SkinBioTherapeutics Plc (5KW.F)

0.2260 -0.0060 (-2.59%) 市場開市。 截至 09:18AM CEST。

SkinBioTherapeutics Plc

The Core
Bath Lane Newcastle Helix
Newcastle upon Tyne NE4 5TF
United Kingdom
44 19 1495 7325
https://www.skinbiotherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 12

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Stuart John Ashman	CEO & Exec. Director	403.56k	無	1967
Mr. Manprit Singh Randhawa	CFO, Sec. & Director	220.43k	無	1984
Dr. Catherine O'Neill	Chief Scientific Officer & Member of Scientific Advisory Board	無	無	無
Laura Bey	Head of Formulations	無	無	無
Ms. Melissa Greenwell	Group Financial Controller	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health. It develops SkinBiotix technology that can enhance the formation of multi-protein complexes and prevent passage toxins, molecules, and ions, as well as pathogens; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has a collaboration agreement with Croda Plc; and the University of Manchester to develop bacterial lysates in the prevention of periodontal gun disease. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

公司管治

截至 無 止，SkinBioTherapeutics Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。